523 related articles for article (PubMed ID: 32619413)
1. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
Stevens TW; Haasnoot ML; D'Haens GR; Buskens CJ; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Mol B; Stokkers PCF; Bemelman WA; Ponsioen CY;
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):900-907. PubMed ID: 32619413
[TBL] [Abstract][Full Text] [Related]
2. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Ponsioen CY; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Bossuyt PMM; Hart A; Warusavitarne J; Buskens CJ; van Bodegraven AA; Brink MA; Consten ECJ; van Wagensveld BA; Rijk MCM; Crolla RMPH; Noomen CG; Houdijk APJ; Mallant RC; Boom M; Marsman WA; Stockmann HB; Mol B; de Groof AJ; Stokkers PC; D'Haens GR; Bemelman WA;
Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):785-792. PubMed ID: 28838644
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.
de Groof EJ; Stevens TW; Eshuis EJ; Gardenbroek TJ; Bosmans JE; van Dongen JM; Mol B; Buskens CJ; Stokkers PCF; Hart A; D'Haens GR; Bemelman WA; Ponsioen CY;
Gut; 2019 Oct; 68(10):1774-1780. PubMed ID: 31233395
[TBL] [Abstract][Full Text] [Related]
4. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).
Eshuis EJ; Bemelman WA; van Bodegraven AA; Sprangers MA; Bossuyt PM; van Milligen de Wit AW; Crolla RM; Cahen DL; Oostenbrug LE; Sosef MN; Voorburg AM; Davids PH; van der Woude CJ; Lange J; Mallant RC; Boom MJ; Lieverse RJ; van der Zaag ES; Houben MH; Vecht J; Pierik RE; van Ditzhuijsen TJ; Prins HA; Marsman WA; Stockmann HB; Brink MA; Consten EC; van der Werf SD; Marinelli AW; Jansen JM; Gerhards MF; Bolwerk CJ; Stassen LP; Spanier BW; Bilgen EJ; van Berkel AM; Cense HA; van Heukelem HA; van de Laar A; Slot WB; Eijsbouts QA; van Ooteghem NA; van Wagensveld B; van den Brande JM; van Geloven AA; Bruin KF; Maring JK; Oldenburg B; van Hillegersberg R; de Jong DJ; Bleichrodt R; van der Peet DL; Dekkers PE; Goei TH; Stokkers PC
BMC Surg; 2008 Aug; 8():15. PubMed ID: 18721465
[TBL] [Abstract][Full Text] [Related]
5. Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus infliximab for terminal ileitis in Crohn's disease: a randomised, controlled, open-label trial.
Hao X; Feng T; Yang Y; Shi Y; Jing R; Liu S; Luo Y; Qiao Y; Zhong M; Yu M
BMJ Open; 2020 Nov; 10(11):e038429. PubMed ID: 33199421
[TBL] [Abstract][Full Text] [Related]
6. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.
Kotze PG; Yamamoto T; Danese S; Suzuki Y; Teixeira FV; de Albuquerque IC; Saad-Hossne R; de Barcelos IF; da Silva RN; da Silva Kotze LM; Olandoski M; Sacchi M; Yamada A; Takeuchi K; Spinelli A
J Crohns Colitis; 2015 Jul; 9(7):541-7. PubMed ID: 25820017
[TBL] [Abstract][Full Text] [Related]
7. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.
Rodríguez-Lago I; Hoyo JD; Pérez-Girbés A; Garrido-Marín A; Casanova MJ; Chaparro M; Fernández-Clotet A; Castro-Poceiro J; García MJ; Sánchez S; Ferreiro-Iglesias R; Bastón I; Piqueras M; Careda LEIB; Mena R; Suárez C; Cordón JP; López-García A; Márquez L; Arroyo M; Alfambra E; Sierra M; Cano N; Delgado-Guillena P; Morales-Alvarado V; Aparicio JC; Guerra I; Aulló C; Merino O; Arranz L; Hidalgo MA; Llaó J; Plaza R; Molina G; Torres P; Pérez-Galindo P; Romero MG; Herrera-deGuise C; Armesto E; Mesonero F; Frago-Larramona S; Benítez JM; Calvo M; Martín MDCL; Elorza A; Larena A; Peña E; Rodríguez-Grau MDC; Miguel-Criado J; Botella B; Olmos JA; López L; Aguirre U; Gisbert JP;
United European Gastroenterol J; 2020 Nov; 8(9):1056-1066. PubMed ID: 32723069
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
Chanchlani N; Lin S; Bewshea C; Hamilton B; Thomas A; Smith R; Roberts C; Bishara M; Nice R; Lees CW; Sebastian S; Irving PM; Russell RK; McDonald TJ; Goodhand JR; Ahmad T; Kennedy NA;
Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):521-538. PubMed ID: 38640937
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
[TBL] [Abstract][Full Text] [Related]
10. Effect of a concomitant elemental diet with maintenance anti-tumor necrosis factor-α antibody therapy in patients with Crohn's disease: A multicenter, prospective cohort study.
Hirai F; Ishida T; Takeshima F; Yamamoto S; Yoshikawa I; Ashizuka S; Inatsu H; Mitsuyama K; Sou S; Iwakiri R; Nozaki R; Ohi H; Esaki M; Iida M; Matsui T;
J Gastroenterol Hepatol; 2019 Jan; 34(1):132-139. PubMed ID: 29935082
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for anastomotic recurrence after primary ileocaecal resection in Crohn's disease.
Aaltonen G; Keränen I; Carpelan-Holmström M; Lepistö A
Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1143-1147. PubMed ID: 30024490
[TBL] [Abstract][Full Text] [Related]
12. Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres.
de Buck van Overstraeten A; Eshuis EJ; Vermeire S; Van Assche G; Ferrante M; D'Haens GR; Ponsioen CY; Belmans A; Buskens CJ; Wolthuis AM; Bemelman WA; D'Hoore A
Br J Surg; 2017 Nov; 104(12):1713-1722. PubMed ID: 28745410
[TBL] [Abstract][Full Text] [Related]
13. Transcending conventional therapies: the role of biologic and other novel therapies.
Sandborn WJ
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
[TBL] [Abstract][Full Text] [Related]
14. Modified Side-To-Side Isoperistaltic Strictureplasty over the Ileocaecal Valve: An Alternative to Ileocaecal Resection in Extensive Terminal Ileal Crohn's Disease.
de Buck van Overstraeten A; Vermeire S; Vanbeckevoort D; Rimola J; Ferrante M; Van Assche G; Wolthuis A; D'Hoore A
J Crohns Colitis; 2016 Apr; 10(4):437-42. PubMed ID: 26674959
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Vuijk SA; Jongsma MME; Hoeven BM; Cozijnsen MA; van Pieterson M; de Meij TGJ; Norbruis OF; Groeneweg M; Wolters VM; van Wering H; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg S; Rizopoulos D; Poley MJ; Escher JC; de Ridder L
Aliment Pharmacol Ther; 2024 Jun; 59(12):1510-1520. PubMed ID: 38644588
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
17. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
18. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence.
Regueiro M; Kip KE; Baidoo L; Swoger JM; Schraut W
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1494-502.e1. PubMed ID: 24440221
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
[TBL] [Abstract][Full Text] [Related]
20. Real-world Experience of Anti-tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease: A Retrospective Multicenter Cohort Study.
Kobayashi T; Hishida A; Tanaka H; Nuki Y; Bamba S; Yamada A; Fujii T; Shinzaki S; Yokoyama Y; Yoshida A; Ozeki K; Ashizuka S; Kamata N; Nanjo S; Kakimoto K; Nakamura M; Matsui A; Yamauchi R; Takahashi S; Tomizawa T; Yoshino T; Hibi T
Inflamm Bowel Dis; 2017 Dec; 23(12):2245-2251. PubMed ID: 29084079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
